NuvOx Therapeutics, Inc. S-1/Aamended IPO prospectus

Executive Summary

NuvOx Therapeutics develops NanO₂, an intravenous oxygen therapeutic targeting glioblastoma, ischemic stroke and acute respiratory distress syndrome; it has no approved products or product-sales revenue. FY2025 revenue, predominantly research grants, rose 91% to $0.980M, but operating loss reached $(5.10)M; H1 2026 revenue declined 4.2% and operating loss widened. The unpriced, all-primary IPO would raise $17.2M–$22.9M gross at $6.00–$8.00, implying an $80.0M–$107M market capitalization and 21.4% ownership for IPO buyers before additional dilution. This is a clinical-development investment, not a commercial-growth story: the anticipated early-2027 glioblastoma readout is the principal near-term test, while the IPO funds development but not the full path to approval.

The Offering

• Size and implied valuation: 2.86M newly issued shares at $6.00–$8.00 generate $17.2M–$22.9M gross. Using 13,339,579 post-offering shares, implied capitalization is $80.0M–$107M, or 81.7–109 times FY2025 grant-led revenue; buyers receive 21.4%. Including disclosed options, warrants, anticipated executive options and 68,750 reserved plan shares gives 15,592,352 potential shares, $93.6M–$125M capitalization and an 18.3% buyer stake; some awards require approval.
• Proceeds and recipients: at the assumed $7.00 midpoint, gross proceeds are $20.0M and estimated net proceeds $17.4M, all to NuvOx rather than selling stockholders. ThinkEquity leads the offering, with a 7% underwriting discount. Proposed listing: NYSE American, NUOX, subject to approval.
• Over-allotment: a 45-day option covers 429,000 additional shares; full exercise raises estimated midpoint net proceeds to $20.2M and buyers’ ownership to 23.9%.
• Spending priorities: $5.0M for completing Phase IIb glioblastoma, $0.5M for stroke-trial supply, $0.5M for completing Phase Ib respiratory distress, $1.0M for Phase III glioblastoma preparation and $6.0M for Phase II respiratory distress; the remaining ≈$4.4M supports development and working capital.
• Capitalization bridge: before offering proceeds, preferred shares, $12.9M of note principal and accrued interest, and a $0.150M convertible grant convert into common stock. Subsequent financing and share-authorization corrections also enter the illustrative capitalization; this is primarily liability conversion, not cash repayment.
• Asset backing and resale: each $7.00 share is backed by $1.01 of net tangible assets after the IPO, a $5.99 gap; existing holders’ average consideration is $2.11 per share. Company and current-holder lock-ups run six months, versus 12 months for directors and executive officers; later resales and award exercises can expand supply.

Key Financial Highlights

Amounts in $M. Annual FY2024 figures are restated; interim figures are unaudited. “After IPO” assumes specified conversions and adjustments plus the offering at $7.00.

• Earnings quality: H1’s narrower net loss reflects noncash financing valuations and a $4.22M amendment gain, not operating improvement. Stock-based compensation rose to $1.29M, while research spending declined after glioblastoma enrollment and treatment finished.
• Cash-flow divergence: noncash financing losses inflate net losses; FY2025 operating cash use also benefited from $1.9M of working-capital support, mainly increased payables.
• Equity bridge: the $42.3M accumulated deficit and substantial financing liabilities explain negative equity. Conversions and other adjustments improve equity to $(3.12)M before offering proceeds; the IPO then produces positive equity, including removal of $0.841M deferred financing costs from assets.
• Liability interpretation: the capitalization table’s broader “total debt” is $27.2M before the IPO and $0.789M afterward, including warrants and a $0.153M government disaster loan. The historical figure also includes an excess-share-issuance liability, so it is not cash borrowing alone.
• Runway: management expects existing cash and IPO proceeds to support at least 12 months, but pivotal trials and commercialization require further financing.

Business Model and Growth Drivers

Current revenue reimburses qualifying research costs or milestones; it does not measure drug demand. Grants provided $0.975M of FY2025 revenue, and one customer represented all grant receivables.

NanO₂’s droplets convert to gas at body temperature and are intended to oxygenate deprived tissue. Management’s strategy is to establish efficacy across several indications using one therapeutic platform:

• Glioblastoma: the randomized Phase IIb RESTORE trial treated 93 patients; its primary endpoint is progression-free survival, with final results anticipated in early 2027. An earlier 11-patient study reported median survival of 591 days vs 444 days in historical controls, but was not confirmatory.
• Stroke: investigator-led NOVEL treated 23 of ≈150 planned patients; a separate U.S. Phase IIb trial is authorized but not underway.
• Respiratory distress: Phase Ib treated 15 patients with preliminary oxygenation signals; Health Canada allowed Phase II development.

Manufacturing is currently small-batch and in-house. Commercial development requires validated production and transfer or duplication at a contract manufacturer.

Governance and Control

• Voting and influence: common stock has one vote per share; preferred shares convert at closing. Executive Chairman Evan Unger is expected to hold 25.0% beneficial ownership, CEO Rong Wang 6.5%, and directors and executives collectively 36.8%.
• Board protections: five of seven planned directors are independent, but a staggered board and a 66⅔% threshold for specified charter changes constrain shareholder-led change.
• Related parties and awards: facilities are leased from an Unger-connected entity, with shared costs involving his other company. Anticipated post-offering options cover 730,898 shares for Unger and Wang, subject to approvals.
• Reporting: emerging-growth and smaller-company exemptions reduce disclosures and remove auditor attestation of internal controls.

Risk Assessment

• Audit and controls: going-concern doubt, restated FY2024 results and unresolved accounting weaknesses undermine confidence in both funding continuity and reporting.
• Financing dependence: older notes remain unpaid after maturity, and IPO funds do not cover multiple advanced trials; delays could force program cuts or further dilution.
• Clinical concentration: NanO₂ is the only clinical-stage candidate; RESTORE recorded 49 serious adverse events in 25 patients, including two possibly related to treatment or placebo, and efficacy remains unproven.
• Supply continuity: one active-ingredient supplier, one manufacturing site without backup and unvalidated processes create trial-interruption and scale-up exposure.
• Intellectual property: no completed freedom-to-operate analysis, potential University of Florida claims and unresolved commercial consent for Glasgow trial-created intellectual property could constrain commercialization.
• Key personnel: nine employees and two consultants leave execution dependent on key executives and specialized personnel; departures could disrupt development.
• Valuation: 81.7–109 times grant-led revenue cannot be supported by current operations; value depends on successful trials and subsequent financing.

Investor Actionables

Buyers must accept clinical and funding risk rather than an earnings-based valuation. Proceeds primarily finance current trials, a respiratory-distress Phase II trial and initial pivotal glioblastoma preparation.

• RESTORE readout: test the 93-patient trial against its progression-free-survival endpoint in early 2027; supportive efficacy and manageable safety support Phase III, while weak results undermine the lead program.
• Other indications: track NOVEL’s 23-of-≈150 enrollment and respiratory development beyond 15 treated patients; expanding evidence supports the platform, while stalled recruitment or adverse findings weaken it.
• Funding durability: compare deployment against $13.0M of specified clinical allocations; completed milestones support the financing case, while redirection or another raise before delivery weakens it.
• Reporting reliability: check remediation of clinical accrual and financing-valuation weaknesses; clean subsequent filings support confidence, while further corrections challenge it.